CA2272402A1 - Granules comprising clavulanate and one or more excipients - Google Patents

Granules comprising clavulanate and one or more excipients Download PDF

Info

Publication number: CA2272402A1
Authority: CA; Canada
Prior art keywords: granules; clavulanate; anyone; excipients; roller compactor
Prior art date: 1997-11-17
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002272402A

Other languages

English (en)

French (fr)

Inventor

Jan Willem Groenendaal

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

DSM Delft BV

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-11-17

Filing date

1998-11-09

Publication date

1999-05-27

1998-11-09 Application filed by Individual filed Critical Individual

1999-05-27 Publication of CA2272402A1 publication Critical patent/CA2272402A1/en

Status Abandoned legal-status Critical Current

Links

239000008187 granular material Substances 0.000 title claims abstract description 81
239000000546 pharmaceutical excipient Substances 0.000 title claims abstract description 30
HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 title claims abstract description 21
HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 title claims abstract description 21
229940090805 clavulanate Drugs 0.000 title claims abstract description 19
238000000034 method Methods 0.000 claims abstract description 26
238000007873 sieving Methods 0.000 claims abstract description 19
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 4
ABVRVIZBZKUTMK-JSYANWSFSA-M potassium clavulanate Chemical group [K+].[O-]C(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 ABVRVIZBZKUTMK-JSYANWSFSA-M 0.000 claims description 30
LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 claims description 22
239000003826 tablet Substances 0.000 claims description 20
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
239000000203 mixture Substances 0.000 claims description 15
229960004920 amoxicillin trihydrate Drugs 0.000 claims description 12
238000002360 preparation method Methods 0.000 claims description 12
229960003022 amoxicillin Drugs 0.000 claims description 10
LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 claims description 10
239000002245 particle Substances 0.000 claims description 10
239000010419 fine particle Substances 0.000 claims description 9
239000000843 powder Substances 0.000 claims description 9
229920000168 Microcrystalline cellulose Polymers 0.000 claims description 7
239000011230 binding agent Substances 0.000 claims description 7
235000019813 microcrystalline cellulose Nutrition 0.000 claims description 7
239000008108 microcrystalline cellulose Substances 0.000 claims description 7
229940016286 microcrystalline cellulose Drugs 0.000 claims description 7
239000002775 capsule Substances 0.000 claims description 5
239000001913 cellulose Substances 0.000 claims description 4
235000010980 cellulose Nutrition 0.000 claims description 4
229920002678 cellulose Polymers 0.000 claims description 4
238000003801 milling Methods 0.000 claims description 4
239000002904 solvent Substances 0.000 claims description 4
230000035699 permeability Effects 0.000 claims description 3
239000006188 syrup Substances 0.000 claims description 3
235000020357 syrup Nutrition 0.000 claims description 3
239000006186 oral dosage form Substances 0.000 claims description 2
230000003134 recirculating effect Effects 0.000 claims 1
239000000463 material Substances 0.000 description 10
230000000694 effects Effects 0.000 description 8
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
239000011362 coarse particle Substances 0.000 description 7
238000005469 granulation Methods 0.000 description 7
230000003179 granulation Effects 0.000 description 7
238000000354 decomposition reaction Methods 0.000 description 6
238000005550 wet granulation Methods 0.000 description 6
238000007908 dry granulation Methods 0.000 description 5
238000009491 slugging Methods 0.000 description 5
238000004090 dissolution Methods 0.000 description 4
235000019359 magnesium stearate Nutrition 0.000 description 4
238000005056 compaction Methods 0.000 description 3
239000013078 crystal Substances 0.000 description 3
229940079593 drug Drugs 0.000 description 3
239000003814 drug Substances 0.000 description 3
239000007903 gelatin capsule Substances 0.000 description 3
238000001802 infusion Methods 0.000 description 3
238000002156 mixing Methods 0.000 description 3
239000003960 organic solvent Substances 0.000 description 3
238000009490 roller compaction Methods 0.000 description 3
241000237858 Gastropoda Species 0.000 description 2
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
230000003115 biocidal effect Effects 0.000 description 2
229960003324 clavulanic acid Drugs 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
238000000576 coating method Methods 0.000 description 2
238000009826 distribution Methods 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
238000001035 drying Methods 0.000 description 2
239000000428 dust Substances 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
235000019634 flavors Nutrition 0.000 description 2
239000007788 liquid Substances 0.000 description 2
239000011591 potassium Substances 0.000 description 2
229910052700 potassium Inorganic materials 0.000 description 2
239000000047 product Substances 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
238000005204 segregation Methods 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000006067 antibiotic powder Substances 0.000 description 1
239000003782 beta lactam antibiotic agent Substances 0.000 description 1
239000004067 bulking agent Substances 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
239000007910 chewable tablet Substances 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
239000002178 crystalline material Substances 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
239000002274 desiccant Substances 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
239000000945 filler Substances 0.000 description 1
238000011049 filling Methods 0.000 description 1
238000005429 filling process Methods 0.000 description 1
239000012467 final product Substances 0.000 description 1
238000009472 formulation Methods 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
229910001629 magnesium chloride Inorganic materials 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
239000002491 polymer binding agent Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
238000012216 screening Methods 0.000 description 1
238000000926 separation method Methods 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Inorganic materials [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
229940079832 sodium starch glycolate Drugs 0.000 description 1
239000008109 sodium starch glycolate Substances 0.000 description 1
229920003109 sodium starch glycolate Polymers 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
239000007858 starting material Substances 0.000 description 1
238000003860 storage Methods 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
239000000725 suspension Substances 0.000 description 1
229920001059 synthetic polymer Polymers 0.000 description 1
239000007916 tablet composition Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
150000004684 trihydrates Chemical class 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Communicable Diseases (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Medicinal Preparation (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Investigating Or Analysing Biological Materials (AREA)

CA002272402A 1997-11-17 1998-11-09 Granules comprising clavulanate and one or more excipients Abandoned CA2272402A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP97203576.0		1997-11-17
EP97203576		1997-11-17
PCT/EP1998/007225 WO1999025343A1 (en)	1997-11-17	1998-11-09	Granules comprising clavulanate and one or more excipients

Publications (1)

Publication Number	Publication Date
CA2272402A1 true CA2272402A1 (en)	1999-05-27

Family

ID=8228930

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002272402A Abandoned CA2272402A1 (en)	1997-11-17	1998-11-09	Granules comprising clavulanate and one or more excipients

Country Status (13)

Country	Link
EP (1)	EP0973520A1 (ar)
JP (1)	JP2001516365A (ar)
CN (1)	CN1242705A (ar)
AU (1)	AU1337999A (ar)
BR (1)	BR9806280A (ar)
CA (1)	CA2272402A1 (ar)
CO (1)	CO4980893A1 (ar)
JO (1)	JO2082B1 (ar)
NO (1)	NO993467L (ar)
PL (1)	PL334517A1 (ar)
TR (1)	TR199901584T1 (ar)
WO (1)	WO1999025343A1 (ar)
ZA (1)	ZA9810499B (ar)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6294199B1 (en)	1999-04-13	2001-09-25	Beecham Pharmaceuticals (Pte) Limited	Method of treating a bacterial infection comprising administering amoxycillin
US6878386B1 (en)	1999-04-13	2005-04-12	Beecham Pharmaceuticals (Pte) Limited	Method of treating a bacterial infection comprising amoxycillin and potassium clavulanate
US7250176B1 (en)	1999-04-13	2007-07-31	Beecham Pharmaceuticals (Pte) Limited	Method of treating a bacterial infection
US6756057B2 (en)	2000-10-12	2004-06-29	Beecham Pharmaceuticals (Pte) Limited	Amoxicillin and potassium clavulanate dosage form
EP1330236A2 (en)	2000-10-12	2003-07-30	Beecham Pharmaceuticals (Pte) Limited	Formulation containing amoxicillin
GB0031267D0 (en) *	2000-12-21	2001-01-31	Smithkline Beecham Plc	Novel compositions
AT412344B (de) *	2001-04-12	2005-01-25	Sandoz Ag	Hydrophobisierte teilchen von k-clavulanat
AT413983B (de) *	2001-04-12	2006-08-15	Sandoz Ag	K-clavulanat in der form eines granulates
AU2004234176B2 (en) *	2003-05-02	2010-05-13	Globopharm Pharmazeutische Produktions- Und Handelsgesellschaft M.B.H.	Solid pharmaceutical preparation containing levothyroxine and/or liothyronine salts
US8293272B2 (en) *	2003-05-02	2012-10-23	Globopharm Pharmazeutische Produktions-Und Handelsgesellschaft M.B.H.	Solid pharmaceutical preparation containing levothyroxine and/or liothyronine salts
FI20080352A0 (fi) *	2008-05-09	2008-05-09	Atacama Labs Oy	Prosessi korkean lääkepitoisuuden tabletin valmistamiseksi
US8951562B2 (en)	2006-11-10	2015-02-10	Atacama Labs Oy	Method and apparatus or dry granulation
FI20080351A0 (fi) *	2008-05-09	2008-05-09	Atacama Labs Oy	Prosessi matalan lääkepitoisuuden tabletin valmistamiseksi
FI20080346A0 (fi) *	2008-05-09	2008-05-09	Atacama Labs Oy	Prosessi lisäaineita sisältävän tabletin valmistamiseksi
FI20080353A0 (fi) *	2008-05-09	2008-05-09	Atacama Labs Oy	Prosessi erittäin korkean lääkepitoisuuden tabletin valmistamiseksi
FI20070521A7 (fi)	2006-11-10	2008-05-11	Atacama Labs Oy	Rakeita, tabletteja ja rakeistusmenetelmä
FI20080355A0 (fi) *	2008-05-09	2008-05-09	Atacama Labs Oy	Prosessi metforminia käsittävien tablettien valmistamiseksi
CA2723409C (en)	2008-05-09	2016-11-08	Atacama Labs Oy	Method and apparatus for dry granulation
CN104582692A (zh) *	2012-08-28	2015-04-29	中化帝斯曼制药有限公司荷兰公司	包含抗生素和β-内酰胺酶抑制剂的组合物，其中抗生素和β-内酰胺酶抑制剂中的至少一种是迷你片剂的形式
JP2014062064A (ja) *	2012-09-21	2014-04-10	Ohara Yakuhin Kogyo Kk	バルサルタン含有錠剤の製造方法
JP6141472B2 (ja) *	2016-03-02	2017-06-07	大原薬品工業株式会社	バルサルタン含有錠剤の製造方法
KR20250026366A (ko) *	2017-07-05	2025-02-25	노파르티스 아게	신규한 약학적 조성물
CN110051637A (zh) *	2019-05-21	2019-07-26	葵花药业集团北京药物研究院有限公司	阿莫西林克拉维酸钾制剂及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2251250C3 (de) *	1972-10-19	1981-06-25	Hoechst Ag, 6230 Frankfurt	Verfahren zur Herstellung hochdosierter Antibiotica-Tabletten
NZ187013A (en) *	1977-04-27	1985-04-30	Beecham Group Ltd	9-amino-9-deoxy-clavulanic acid derivatives and pharmaceutical compositions
NZ189022A (en) *	1977-12-08	1981-11-19	Beecham Group Ltd	Pharmaceutically acceptable particles of clavulanates dispersed in a polymeric binder
DE3887179T2 (de) *	1987-03-02	1994-06-16	Brocades Pharma Bv	Pharmazeutische Zusammensetzung, pharmazeutisches Granulat und Verfahren zu ihrer Herstellung.
IL109770A0 (en) *	1993-05-29	1994-11-28	Smithkline Beecham Corp	Thermal infusion process for preparing controlled release solid dosage forms of medicaments for oral administration and controlled release solid dosage forms of medicaments prepared thereby

1998
- 1998-11-09 TR TR1999/01584T patent/TR199901584T1/xx unknown
- 1998-11-09 AU AU13379/99A patent/AU1337999A/en not_active Abandoned
- 1998-11-09 PL PL98334517A patent/PL334517A1/xx unknown
- 1998-11-09 CN CN98801549A patent/CN1242705A/zh active Pending
- 1998-11-09 CA CA002272402A patent/CA2272402A1/en not_active Abandoned
- 1998-11-09 WO PCT/EP1998/007225 patent/WO1999025343A1/en not_active Ceased
- 1998-11-09 EP EP98956907A patent/EP0973520A1/en not_active Withdrawn
- 1998-11-09 JP JP52751299A patent/JP2001516365A/ja active Pending
- 1998-11-09 BR BR9806280-8A patent/BR9806280A/pt not_active Application Discontinuation
- 1998-11-17 JO JO19982082A patent/JO2082B1/ar active
- 1998-11-17 ZA ZA9810499A patent/ZA9810499B/xx unknown
- 1998-11-17 CO CO98067517A patent/CO4980893A1/es unknown
1999
- 1999-07-14 NO NO993467A patent/NO993467L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
AU1337999A (en)	1999-06-07
ZA9810499B (en)	1999-05-24
TR199901584T1 (xx)	2000-01-21
CO4980893A1 (es)	2000-11-27
PL334517A1 (en)	2000-02-28
WO1999025343A1 (en)	1999-05-27
JP2001516365A (ja)	2001-09-25
JO2082B1 (ar)	2000-05-21
EP0973520A1 (en)	2000-01-26
NO993467D0 (no)	1999-07-14
BR9806280A (pt)	2000-02-15
CN1242705A (zh)	2000-01-26
NO993467L (no)	1999-07-14

Legal Events

Date	Code	Title	Description
2002-11-12	FZDE	Discontinued
2023-05-26	FZDE	Discontinued	Effective date: 20021112

Publication	Publication Date	Title
CA2272402A1 (en)	1999-05-27	Granules comprising clavulanate and one or more excipients
WO1999011261A1 (en)	1999-03-11	Granules free of excipients
AU2002237462B2 (en)	2006-05-18	Oral pharmaceutical composition of cefpodoxime proxetil
US8632819B2 (en)	2014-01-21	Microcrystalline cellulose and calcium carbonate compositions useful as recompactible pharmaceutical excipients
US20110135927A1 (en)	2011-06-09	Excipient for compressed tablets comprising novel spherical mannitol
US20040197402A1 (en)	2004-10-07	Oxcarbazepine dosage forms
WO2008104996A2 (en)	2008-09-04	Water dispersible pharmaceutical formulation and process for preparing the same
AU2002237462A1 (en)	2003-03-06	Oral pharmaceutical composition of cefpodoxime proxetil
EP1682096A1 (en)	2006-07-26	Process for preparing clopidogrel compositions
DE60306120T2 (de)	2006-11-09	Pharmazeutische formulierung, die n-((1-n-butyl-4-piperidinyl)menthyl)-3,4-dihydro-2h-(1,3)oxazino(3,2-a)indol-10-carboxamid oder ein entsprechendes salz hiervon enthält, sowie deren herstellungsprozess, welcher trockengranulierung beinhaltet
MXPA01009808A (es)	2002-04-24	Aglomerados por cristalizacion.
HUP0304078A2 (hu)	2004-04-28	Tömörítési eljárás nátrium-fenitoin gyógyszerkészítmény előállítására
WO1997033571A1 (fr)	1997-09-18	Preparation d'ecadotril a microdispersion et liberation rapides
US8062664B2 (en)	2011-11-22	Process for preparing formulations of lipid-regulating drugs
JP4336380B1 (ja)	2009-09-30	水懸濁性を向上させた細粒剤
JP2000516601A (ja)	2000-12-12	水溶性化合物及びセルロースを含有する粒状物
JPH10502937A (ja)	1998-03-17	フシジン酸錠剤の製法
MXPA99006619A (en)	2000-06-01	Granules comprising clavulanate and one or more excipients
JP2004517111A (ja)	2004-06-10	シタロプラムを含有する薬学的調合物
CA2888856A1 (en)	2014-05-22	Dispersible tablet
HK1023949A (en)	2000-09-29	Granules comprising clavulanate and one or more excipients
JPH05221853A (ja)	1993-08-31	崩壊性良好な生薬類含有造粒物
WO1999020277A1 (en)	1999-04-29	Rapidly soluble drug composition
CZ1398A3 (cs)	1998-05-13	Terapeutické efervescentní kompozice, farmaceutické granuláty a prostředky, způsoby jejich přípravy a použití
CN112190580A (zh)	2021-01-08	用于制备依折麦布片的方法及依折麦布片